Fiche du document
2 février 2022
- doi: 10.53738/REVMED.2022.18.767.182
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.767.182
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35107893
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_BB8819FD31961
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Life, Quality of Melanocytic tumor Malignant melanomaCiter ce document
M.L. Meyer et al., « Oncologie [2021 Oncology update] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.767.182
Métriques
Partage / Export
Résumé
Despite COVID-19 pandemic, which is still deeply affecting world economy and global health, medical oncology specialists keep pursuing their effort for the identification of new therapeutic options to improve patients' life expectancy and quality of life. 2021 confirms the immunotherapy efficacy, alone or in combination with other modalities, across several indications. This year, we are summarizing the new approaches in the following sectors: lung, breast, melanoma, gynecological, digestive, urological and ENT areas.